KSP Inhibitors sponded to st-line docetaxel , although there is no level evidence to support this. Moreov the benes of other chemotherapeutic agents in this setting have been limited . As su the goal of treatment has remained symptom palliation to include analgesi radiotherapy and bisphosphonat with treatment choice often tailored to the individual patient . Although some studies have also shown that bisphosphonates reduce the risk of skeletal-related events in men with mCRPC and bone metastases , their ef acy in this setting remains controversial. Collective these data show that treatment options in the UK for men with mCRPC have been limit and there is a lack of a standard approa particularly in the second-line setting. Treatment decisions are often based on a patient response to thing of the past. Howev as we are faced with the reality of an in x of multiple new treatment optio it will be critical to identify key considerations in our decision-making process and to establish an optim standardized approach to treatment so that new therapies can be assimilated into an mCRPC treatment algorithm and into our routine clinical practice.

Against this backgrou we conducted a survey among UK-based oncologists to evaluate current management strategies for patients with advanced prostate canc to identify key considerations in their decision-making proce and to gain insights into the possible role of emerging therapies in future UK clinical practice. MATERIALS AND METHODS A semi-structured questionnai prising 6 questio was issued by the British Uro-oncology Group to society member which werepleted and returned to the BUG during a closed meeting of society members. The questionnaire waspiled by the authors and was  Dapagliflozin designed to evaluate current st-and second-line treatment strategies in the UK for patients with advanced CR and to identify key factors thought to in ence the clinical decision-making process of the treating physician. The survey was also designed to solicit views on the potential impact of emerging state-of-the-art therapies on the clinical management of patients with CRPC over the next years. Therapies included in this evaluation were selected by the authors as B those currently in late-stage clinical development th in the event of positive phase III da were likely to have the biggest impact on the management of CRPC in the UK. Therapies selected were: abiraterone aceta a?iberce bevacizum cabazitax custirs MDV, sipuleucel-T and zibotentan. RESULTS In September , 8 surveys were distributed to UK-based oncologists and 0 werepleted and returned to the BUG for evaluation.

This surveyprised a similar number of participants to previously reported surveys . The authors believe that the sample size included most prostate cancer oncologists in the UK and hence the dings are of clinical relevance and re ctive of current practice of the confiscation management of advanced mCRPC. Initial questio designed to establish the number of referrals and patients treated each ye showed that responding oncologists in the UK had an average of new referrals for prostate cancer each ye with 4 reporting > new referrals annually .